Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the 17 biotechnology stocks with more than 50% upside.
On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock. Her rating came after Truist Financial updated its projections following a thorough reassessment of the current data regarding the orexin-2 receptor agonist class.
M. A. Arkhipov/Shutterstock.com
On January 16, Biren Amin from Piper Sandler maintained an Overweight rating on Centessa Pharmaceuticals (NASDAQ:CNTA). He forecasted a $38 price target for the stock, which implied a 57% upside potential.
Amin highlighted two major catalysts expected this quarter. These include the planned initiation of Phase 3 trials for ORX750 across NT1, NT2, and IH, along with additional findings from the CRYSTAL-1 Phase 2 study. The analyst is optimistic about idiopathic hypersomnia as it may represent a larger and potentially underappreciated market opportunity.
Centessa Pharmaceuticals (NASDAQ:CNTA) is involved in the discovery and development of transformative medicines for neurological and neurodegenerative diseases. The company operates under an asset-centric Research and Development model, with a portfolio of subsidiaries that support specialized research programs. These individual programs are treated as separate entities to ensure highly efficient, data-driven decision-making.
While we acknowledge the potential of CNTA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. This article is originally published at Insider Monkey.
